LGALS3 and melanoma: Until November 2017, two clinical trials have been reported using the galectin-3 inhibitor DG-MD-02 along with ipilimumab (anti-CTLA-4) or pembrolizumab (anti-PD-1) to treat patients diagnosed with melanomas, non-small cell lung cancers, and squamous cell head and neck cancers (Table 2).